D. Gordon

发表

Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.

A. Howell, J. Mackey, A. Belch, 2001, Cancer journal.

Randomized multinational phase 3 trial of dacarbazine (DTIC) with or without Bcl-2 antisense (oblimersen sodium) in patients (pts) with advanced malignant melanoma (MM): Analysis of long-term survival.

H. Pehamberger, M. Gore, M. Millward, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Randomized, Double-Blind, Placebo-Controlled, Phase III Noninferiority Study of the Long-Term Safety and Efficacy of Darbepoetin alfa for Chemotherapy-Induced Anemia in Patients With Advanced Non-Small Cell Lung Cancer.

K. Syrigos, P. Gascón, C. Barrios, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Naproxen sodium in treatment of bone pain due to metastatic cancer

F. Meyskens, C. Jacobs, D. Gordon, 1988, Pain.

P107 Zoledronic acid is superior to pamidronate in patients with breast cancer and multiple myeloma who are at high risk for skeletal complications

L. Rosen, Y. Hei, M. Zheng, 2005 .

P104 Continuing benefit of zoledronic acid for the prevention of skeletal complications in breast cancer patients with bone metastases

A. Howell, A. Belch, L. Rosen, 2005 .

Zoledronic acid versus pamidronate in patients with breast cancer and multiple myeloma who are at high risk for skeletal complications.

L. Rosen, Y. Hei, M. Zheng, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treating Anemia of Cancer with Darbepoetin Alfa Administered Every 4 Weeks: Final Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study in Cancer Patients Not Receiving Chemotherapy and/or Radiotherapy.

Carole B. Miller, D. Gordon, G. Nichols, 2006 .

Treating anemia of cancer with every-4-week darbepoetin alfa: final efficacy and safety results from a phase II, randomized, double-blind, placebo-controlled study.

Tom Lillie, Carole B. Miller, David Gordon, 2008, The oncologist.

Long‐term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors

M. Krzakowski, L. Rosen, P. de Souza, 2004, Cancer.

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the MK2 Inhibitor ATI-450 in Healthy Subjects: A Placebo-Controlled, Randomized Phase 1 Study

J. Monahan, E. Hellriegel, H. Hope, 2021, Clinical pharmacology : advances and applications.

A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy

G. Demetri, A. Saven, J. Rigas, 2001, British Journal of Cancer.

Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion

L. Rosen, R. Coleman, J. Simeone, 2004, Cancer.

Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group.

M. Krzakowski, L. Rosen, P. de Souza, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long‐term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma

A. Howell, J. Mackey, A. Belch, 2003, Cancer.

The New Bisphosphonate, Zometa® (Zoledronic Acid), Decreases Skeletal Complications in Both Osteolytic and Osteoblastic Lesions: A Comparison to Pamidronate

F. Saad, E. Small, L. Rosen, 2002, Cancer investigation.

Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials.

D. Gordon, 2005, Clinical breast cancer.

Zoledronic acid is superior to pamidronate in patients with breast cancer and bone metastases

A. Howell, L. Rosen, R. Coleman, 2003 .

Treatment of inoperable non‐small cell carcinoma of the lung with radiation therapy, with or without levamisole: A randomized trial of the Southeastern Cancer Study Group

C. Perez, J. Durant, R. Birch, 1984, American journal of clinical oncology.